Unia Europejska -
norweski -
EMA (European Medicines Agency)
lamivudine/zidovudine teva
teva pharma b.v. - lamivudine, zidovudine - hiv-infeksjoner - antivirale midler til systemisk bruk - lamivudin / zidovudin teva er angitt i antiretroviral kombinationsbehandling for behandling av hiv-infeksjon (human immunodeficiency virus).
Unia Europejska -
norweski -
EMA (European Medicines Agency)
thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - thalidomid - multippelt myelom - immunsuppressive - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
Norwegia -
norweski -
Statens legemiddelverk
methotrexate sanoswiss 2.5 mg
sanoswiss uab - metotreksat - tablett - 2.5 mg
Norwegia -
norweski -
Statens legemiddelverk
mitoxantron ebewe 2 mg/ ml
ebewe pharma ges.m.b.h nfg. kg - mitoksantronhydroklorid - konsentrat til infusjonsvæske, oppløsning - 2 mg/ ml
Norwegia -
norweski -
Statens legemiddelverk
novantrone 2 mg/ ml
viatris as - mitoksantronhydroklorid - konsentrat til infusjonsvæske, oppløsning - 2 mg/ ml
Norwegia -
norweski -
Statens legemiddelverk
trimonil retard 300 mg
desitin arzneimittel gmbh - karbamazepin - depottablett - 300 mg
Norwegia -
norweski -
Statens legemiddelverk
trimonil retard 150 mg
desitin arzneimittel gmbh - karbamazepin - depottablett - 150 mg
Norwegia -
norweski -
Statens legemiddelverk
trimonil retard 600 mg
desitin arzneimittel gmbh - karbamazepin - depottablett - 600 mg
Unia Europejska -
norweski -
EMA (European Medicines Agency)
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastiske midler - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
Norwegia -
norweski -
Statens legemiddelverk
ethosuximide orifarm 250 mg
orifarm generics a/s - etosuksimid - kapsel, myk - 250 mg